271 related articles for article (PubMed ID: 32379785)
1. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T; Kakizaki S; Uehara D; Nagashima T; Ueno T; Namikawa M; Saito S; Hosonuma K; Suzuki H; Naganuma A; Takagi H; Sato K; Uraoka T
Intern Med; 2019 Jul; 58(13):1835-1844. PubMed ID: 30918170
[TBL] [Abstract][Full Text] [Related]
3. Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Stefanini B; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Della Corte A; Ratti F; De Cobelli F; Aldrighetti L; Scartozzi M; Cascinu S; Casadei-Gardini A
Oncology; 2023; 101(5):283-291. PubMed ID: 36657420
[TBL] [Abstract][Full Text] [Related]
4. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
5. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
[TBL] [Abstract][Full Text] [Related]
6. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
7. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib.
Yılmaz A; Şimşek M; Hannarici Z; Büyükbayram ME; Bilici M; Tekin SB
Future Oncol; 2021 Nov; 17(33):4545-4559. PubMed ID: 34431372
[No Abstract] [Full Text] [Related]
8. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
10. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
11. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
Marasco G; Colecchia A; Bacchi Reggiani ML; Celsa C; Farinati F; Giannini EG; Benevento F; Rapaccini GL; Caturelli E; Di Marco M; Biasini E; Marra F; Morisco F; Foschi FG; Zoli M; Gasbarrini A; Baroni GS; Masotto A; Sacco R; Raimondo G; Azzaroli F; Mega A; Vidili G; Brunetto MR; Nardone G; Dajti E; Ravaioli F; Avanzato F; Festi D; Trevisani F;
Dig Liver Dis; 2021 Aug; 53(8):1011-1019. PubMed ID: 33353858
[TBL] [Abstract][Full Text] [Related]
12. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI).
Pinato DJ; North BV; Sharma R
Br J Cancer; 2012 Apr; 106(8):1439-45. PubMed ID: 22433965
[TBL] [Abstract][Full Text] [Related]
13. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
[TBL] [Abstract][Full Text] [Related]
14. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Jiang Y; Tu X; Zhang X; Liao H; Han S; Jiang W; Zheng Y; Zhao P; Tong Z; Fu Q; Qi Q; Shen J; Zhong L; Pan Y; Fang W
Support Care Cancer; 2020 Nov; 28(11):5569-5579. PubMed ID: 32361828
[TBL] [Abstract][Full Text] [Related]
15. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
Rimini M; Yoo C; Lonardi S; Masi G; Piscaglia F; Kim HD; Rizzato MD; Salani F; Ielasi L; Forgione A; Bang Y; Soldà C; Catanese S; Sansone V; Ryu MH; Ryoo BY; Burgio V; Cucchetti A; Cascinu S; Casadei-Gardini A
Hepatol Res; 2021 Jul; 51(7):796-802. PubMed ID: 34005839
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte to monocyte ratio and prognostic nutritional index predict survival outcomes of hepatitis B virus-associated hepatocellular carcinoma patients after curative hepatectomy.
Wu SJ; Lin YX; Ye H; Li FY; Xiong XZ; Cheng NS
J Surg Oncol; 2016 Aug; 114(2):202-10. PubMed ID: 27199001
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Nutritional Index as a Prognostic Factor for Very Early-Stage Hepatocellular Carcinoma.
Ho CT; Chia-Hui Tan E; Lee PC; Chu CJ; Huang YH; Huo TI; Hou MC; Wu JC; Su CW
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00678. PubMed ID: 38240325
[TBL] [Abstract][Full Text] [Related]
18. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
[TBL] [Abstract][Full Text] [Related]
19. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]